Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Immunology

Effect of Isotype on Internalization and Cytotoxicity of CD19-Ricin A Immunotoxins

Ypke V. J. M. van Oosterhout, Ingrid E. van den Herik-Oudijk, Hans M. C. Wessels, Theo de Witte, Jan G. J. van de Winkel and Frank W. M. B. Preijers
Ypke V. J. M. van Oosterhout
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid E. van den Herik-Oudijk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans M. C. Wessels
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theo de Witte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan G. J. van de Winkel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank W. M. B. Preijers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published July 1994
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

We analyzed the effect of isotype variation on effectiveness of B-cell CD19 immunotoxins (IT) by using class switch variants (CLB-B4-IgG1 and CLB-B4-IgG2a) conjugated to ricin A. Notably, IgG1-IT appeared to be ∼100-fold more potent than IgG2a-IT toward B-cell lines Daudi and KM3. Binding and internalization studies with 125I-labeled monoclonal antibodies (mAbs) revealed a higher cellular uptake of IgG1 compared to IgG2a, despite similar binding affinities. Following removal of the Fc part, both mAbs internalized at the same rate as IgG2a, indicating that the Fc part of IgG1 is involved in enhanced cellular uptake. The involvement of FcγRII (CD32) in this process was demonstrated by a decreased cytotoxicity of IgG1-IT (and not IgG2a-IT) in the presence of FcγRII-blocking mAbs AT10 or IV.3. To identify the isoform responsible for this phenomenon, internalization of IgG1 and IgG2a in 11 B-cell lines and malignant B-cells of 8 patients was compared with expression of FcγRII subclasses. In addition to four cell lines (Daudi, KM3, Nalm6, and Raji), the malignant B-cells of two patients showed enhanced uptake of IgG1 relative to IgG2a. Only the FcγRIIa transcript was found in all B-cells. Furthermore, enhanced uptake of IgG1 correlated with rosetting of erythrocytes sensitized with anti-glycophorin A mAb of IgG1 isotype rather than with FcγRIIa membrane expression levels. These data support the idea that functional FcγRIIa is involved in the enhanced IgG1 uptake observed in a subset of B-cells. Our study, therefore, points to an important role for the Fc region of IT in the delivery of cytotoxic effects.

Footnotes

  • ↵1 This work was supported in part by grants from the Ank van Vlissingen Foundation and the Maurits and Anna de Kock Foundation.

  • ↵2 To whom requests for reprints should be addressed.

  • Received February 16, 1994.
  • Accepted May 2, 1994.
  • ©1994 American Association for Cancer Research.
PreviousNext
Back to top
July 1994
Volume 54, Issue 13
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Isotype on Internalization and Cytotoxicity of CD19-Ricin A Immunotoxins
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of Isotype on Internalization and Cytotoxicity of CD19-Ricin A Immunotoxins
Ypke V. J. M. van Oosterhout, Ingrid E. van den Herik-Oudijk, Hans M. C. Wessels, Theo de Witte, Jan G. J. van de Winkel and Frank W. M. B. Preijers
Cancer Res July 1 1994 (54) (13) 3527-3532;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effect of Isotype on Internalization and Cytotoxicity of CD19-Ricin A Immunotoxins
Ypke V. J. M. van Oosterhout, Ingrid E. van den Herik-Oudijk, Hans M. C. Wessels, Theo de Witte, Jan G. J. van de Winkel and Frank W. M. B. Preijers
Cancer Res July 1 1994 (54) (13) 3527-3532;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Immunology

  • Abstract 6686: SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner
  • Abstract 6678: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy
  • Abstract 6644: A comprehensive in vitro and in vivo system to evaluate STING agonist efficacy in cancer therapeutics
Show more Immunology

Articles

  • Imprinting of a Genomic Domain of 11p15 and Loss of Imprinting in Cancer: An Introduction
  • The Phenotypes Associated with ret Mutations in the Multiple Endocrine Neoplasia Type 2 Syndrome
  • Organizational Structure: General Motors Cancer Research Foundation
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement